{
	"kja6iycmText": "Mahableshwarkar AR e<span class=\"_ _0\"></span>t al.<span class=\"_ _0\"></span> 20<span class=\"_ _3\"></span>1<span class=\"_ _3\"></span>5<span class=\"_ _3\"></span><span class=\"fs1 ls5 v1\">1</span>",
	"kja6iycnText": "A randomise<span class=\"_ _0\"></span>d, placebo<span class=\"_ _0\"></span>-cont<span class=\"_ _0\"></span>rolled, ac<span class=\"_ _0\"></span>ti<span class=\"_ _0\"></span>ve-re<span class=\"_ _0\"></span>ference, double<span class=\"_ _0\"></span>-blind, flexible<span class=\"_ _0\"></span>-<span class=\"_ _0\"></span>dose <br><span class=\"ls4 wsb\">s<span class=\"_ _0\"></span>tudy of the efficac<span class=\"_ _0\"></span>y of Brin<span class=\"_ _2\"></span>tel<span class=\"_ _2\"></span>lix<span class=\"_ _2\"></span>® on co<span class=\"_ _2\"></span>gnit<span class=\"_ _2\"></span>ive fu<span class=\"_ _2\"></span>nction in MD<span class=\"_ _2\"></span>D&nbsp;(CONNECT study).</span>",
	"kja6iycoText": "Key inclusion criteria ",
	"kja6iycpText": "P<span class=\"_ _c\"></span>atients with diagnosis<span class=\"_ _0\"></span> <br>of acute MDE in the<span class=\"_ _0\"></span> <br>context of recurrent MDD <br>according to DSM-IV ",
	"kja6iycqText": "18-65 years of age<span class=\"_ _0\"></span> ",
	"kja6iycrText": "Moderate to sever<span class=\"_ _2\"></span>e depression; <br>MADRS ≥26 at screening and <br><span class=\"ws81\">baseline </span>",
	"kja6iycsText": "Current MDE dura<span class=\"_ _2\"></span>tion of  <span class=\"_ _e\"> </span> <br>≥3 months",
	"kja6iyctText": "Self-reported cognitive <br>dysfunction",
	"kja6iycuText": "One-week ",
	"kja6iycvText": "double-blind ",
	"kja6iycwText": "taper period",
	"kja6iycxText": "Back",
	"kja6iycyText": "Dulox<span class=\"_ _2\"></span>etine 60 mg/day (n=207)",
	"kja6iyczText": "Brintellix® 10/20 mg/day (n=196) <br><span class=\"ff3\">10 mg/day on days 1-7 with the <br>option to then increase to 20 mg/day </span>",
	"kja6iyd0Text": "at the end of week 1. Flexible 10/20 <br>mg dose for remaining seven weeks",
	"kja6iyd1Text": "Placebo 60 mg/day (n=191)",
	"kja6iyd2Text": "Randomisation <br><span class=\"ls2a ws85\">1:<span class=\"_ _0\"></span>1:1<span class=\"_ _1\"></span> <br><span class=\"ls45 ws8c\">(A<span class=\"_ _1\"></span>P<span class=\"_ _0\"></span>T<span class=\"_ _0\"></span>S<span class=\"_ _0\"></span> n<span class=\"_ _0\"></span>=59<span class=\"_ _0\"></span>4)</span></span>",
	"kja6iyd3Text": "Patient <br><span class=\"ls46 ws7b\">assessment<span class=\"_ _0\"></span> <br><span class=\"ls1a wsb\">at week 8</span></span>",
	"kja6iyd4Text": "Primary st<span class=\"_ _0\"></span>udy objective: <span class=\"ff3\">to c<span class=\"_ _2\"></span>ompa<span class=\"_ _2\"></span>re the e<span class=\"_ _2\"></span>f<span class=\"_ _0\"></span>fect of <br><span class=\"ls47 ws6d\">Br<span class=\"_ _0\"></span>intellix<span class=\"_ _0\"></span>® wi<span class=\"_ _0\"></span>th pla<span class=\"_ _0\"></span>cebo o<span class=\"_ _0\"></span>n cogni<span class=\"_ _0\"></span>tive<span class=\"_ _0\"></span> func<span class=\"_ _1\"></span>tioning, in<span class=\"_ _0\"></span>cluding<span class=\"_ _0\"></span> <br><span class=\"ls39 ws8d\">speci<span class=\"_ _0\"></span>fic measure<span class=\"_ _0\"></span>s of at<span class=\"_ _1\"></span>tention, execu<span class=\"_ _0\"></span>tive f<span class=\"_ _0\"></span>unc<span class=\"_ _0\"></span>tioning,<span class=\"_ _0\"></span> and <br></span></span>psychomo<span class=\"_ _2\"></span>tor sp<span class=\"_ _2\"></span>eed. P<span class=\"_ _2\"></span>rima<span class=\"_ _2\"></span>r<span class=\"_ _0\"></span>y end<span class=\"_ _2\"></span>poin<span class=\"_ _2\"></span>t was cha<span class=\"_ _2\"></span>nge fr<span class=\"_ _2\"></span>om <br>basel<span class=\"_ _2\"></span>ine t<span class=\"_ _2\"></span>o week 8 i<span class=\"_ _c\"></span>n DSST performan<span class=\"_ _2\"></span>ce scor<span class=\"_ _2\"></span>e vs. pla<span class=\"_ _2\"></span>cebo<span class=\"_ _c\"></span>.</span>",
	"kja6iyd5Text": "Secondary s<span class=\"_ _0\"></span>tud<span class=\"_ _0\"></span>y object<span class=\"_ _0\"></span>ive:<span class=\"ff3 ls36 wsb\"> t<span class=\"_ _2\"></span>o assess the efficacy of <br>Brint<span class=\"_ _2\"></span>ell<span class=\"_ _2\"></span>ix® vs. pl<span class=\"_ _2\"></span>acebo o<span class=\"_ _2\"></span>n depr<span class=\"_ _c\"></span>essive sympto<span class=\"_ _2\"></span>ms an<span class=\"_ _2\"></span>d <br><span class=\"ls38 ws7e\">func<span class=\"_ _0\"></span>t<span class=\"_ _0\"></span>ional capacit<span class=\"_ _0\"></span>y. Secondar<span class=\"_ _0\"></span>y endpoints<span class=\"_ _0\"></span> included change <br></span>from base<span class=\"_ _2\"></span>lin<span class=\"_ _2\"></span>e to we<span class=\"_ _2\"></span>ek 8 in P<span class=\"_ _2\"></span>DQ attentio<span class=\"_ _2\"></span>n/<span class=\"_ _c\"></span>concentra<span class=\"_ _2\"></span>tion <br><span class=\"ls47 ws6d\">and planning<span class=\"_ _0\"></span>/<span class=\"_ _c\"></span>o<span class=\"_ _0\"></span>rganisat<span class=\"_ _0\"></span>ion sub<span class=\"_ _0\"></span>scores<span class=\"_ _0\"></span> and CGI<span class=\"_ _0\"></span>-<span class=\"_ _0\"></span>I score<span class=\"_ _0\"></span> vs.<span class=\"_ _0\"></span> <br><span class=\"ls48 ws8b\">placebo.</span></span></span>",
	"kja6iyd6Text": "Eight-week double-blind treatment period",
	"Brintellix_7520ac85bf": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_75ce868cc5": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Mahableshwarkar AR et al. Neuropsychopharmacol 2015;40:2025-2037.</div>"
}
